Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.49 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | PDE2A | O00408 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22321626 | 0.91 | APP (0.54) | APPMAOBPDE2ANPC1RAB9A | |
| SCHEMBL22321646 | 0.85 | APP (0.57) | APPMAOBPDE2ANPC1RAB9A | |
| SCHEMBL26608275 | 0.84 | MAOB (0.50) | MAOBNPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL26608360 | 0.82 | APP (0.49) | APPMAOBPDE2ANPC1RAB9A | |
| SCHEMBL31658841 | 0.78 | MAOB (0.54) | APPMAOBNPC1RAB9APOLB | |
| SCHEMBL12336074 | 0.78 | ALDH1A1 (0.43) | RAB9APOLBMEN1KMT2A | |
| SCHEMBL310367 | 0.77 | MAOB (0.60) | APPMAOBNPC1RAB9APOLB | |
| SCHEMBL31518022 | 0.77 | NPC1 (0.46) | APPMAOBPDE2ANPC1RAB9A | |
| SCHEMBL25702898 | 0.76 | PDE2A (0.48) | APPMAOBPDE2ANPC1RAB9A | |
| SCHEMBL19785394 | 0.74 | APP (0.48) | APPMAOBPDE2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220482-B2 | Aminopyridinemethanol compounds and their use | UNIVERSITE AMIENS PICARDIE JULES VERNE (FR) | 2022-01-11 | — | — | US | disclosed |
| US-20200255379-A1 | NOVEL AMINOPYRIDINEMETHANOL COMPOUNDS AND THEIR USE | UNIV AMIENS PICARDIE JULES VERNE (FR) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220482-B2 | Aminopyridinemethanol compounds and their use | QDPR, PNMT, CYP3A43 | APP 439/4885MAOB 636/4885PDE2A 442/4885 |
| US-20200255379-A1 | NOVEL AMINOPYRIDINEMETHANOL COMPOUNDS AND THEIR USE | QDPR, PNMT, CYP3A43 | APP 538/4885MAOB 1238/4885PDE2A 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.